newsfilter
← Latest News
PR Newswire·

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

BIOA
  • BioArctic's partner Eisai reported Leqembi global sales of JPY 29.3 billion for Q2 2026.
  • BioArctic received a royalty of SEK 179 million for the quarter, representing a 10% increase compared to Q2 2025.
  • Excluding a JPY 5.3 billion one-time stockpiling effect in China from Q2 2025, royalty revenues grew approximately 43% year-over-year.
  • BioArctic's full Q2 2026 report is scheduled for release on August 26, 2026, at 08:00 CEST.
  • Leqembi is currently approved in 53 countries and under regulatory review in 6 countries.
  • Subcutaneous IV maintenance dosing every four weeks is approved in 8 countries, including the US, UK, China, and Japan.
  • The US FDA approved Leqembi Iqlik for subcutaneous dosing with an autoinjector for early Alzheimer's disease.
  • A new drug application for subcutaneous Leqembi was submitted in Japan in November 2025.
  • Leqembi was added to China's "Commercial Insurance Innovative Drug List" in December 2025.
  • China accepted the Biologics License Application for subcutaneous Leqembi in January 2026 and designated it for priority review in February 2026.
  • Eisai's Phase 3 AHEAD 3-45 study for preclinical Alzheimer's disease is ongoing after full recruitment in October 2024.
  • The Tau NexGen study for Dominantly Inherited Alzheimer's Disease, led by Washington University, is ongoing with lecanemab as the backbone therapy.
  • BioArctic holds commercial rights for the Nordic region and is entitled to sales milestones and global royalties from Eisai.
  • BioArctic's B shares (BIOA B) are listed on Nasdaq Stockholm Large Cap.